Feed aggregator

Accelerating the Dissemination and Implementation of PCOR Findings into Primary Care Practice (R18)

RAC - Health Promotion and Disease Prevention -

Awards funding to disseminate Patient-Centered Outcomes Research (PCOR) findings to primary care practices with the ultimate goal of preventing heart disease, high blood pressure, high cholesterol, and tobacco use. Geographic coverage: Nationwide -- Agency for Healthcare Research and Quality

Requests for Applications: American Diabetes Association and Boehringer Ingelheim Research Award: Chronic Kidney Disease and Renal Insufficiency in the Setting of Diabetes

ScanGrants - Diabetes -

Requests for Applications: American Diabetes Association and Boehringer Ingelheim Research Award: Chronic Kidney Disease and Renal Insufficiency in the Setting of Diabetes

Deadline: September 15, 2014

This award is designed to support basic, clinical or translational research to better understand the issues surrounding the relationship between diabetes and chronic kidney disease (CKD). Specifically, these grants would support research aimed at 1) understanding the mechanisms underlying the development of renal complications in people with diabetes, and 2) improving the treatment and management of people with chronic kidney disease and diabetes.

Support

Basic science projects will receive a maximum of $345,000 over three years ($115,000 per year, including indirect costs). Clinical or translational science projects will receive a maximum of $660,000 over three years ($220,000 per year, including indirect costs). Indirect costs cannot exceed 15% of requested direct costs; if subcontracts are used, any associated indirect costs must be incorporated into the 15% yearly maximum.
 

Programs to Reduce Obesity in High Obesity Areas

RAC - Obesity Funding -

Awards funds to land grant colleges and universities for projects that will work to improve physical activity and nutrition; reduce obesity; and prevent and control diabetes, heart disease, and stroke in areas where adult obesity rates are high. Geographic coverage: Available in 25 states. -- Centers for Disease Control and Prevention

Request for Letters of Intent: Glucose Responsive Insulin Discovery and Validation

ScanGrants - Diabetes -

Request for Letters of Intent: Glucose Responsive Insulin Discovery and Validation

Letter of Interest Deadline: July 11, 2014

JDRF, the world’s leading non-profit organization with the mission to cure, treat and prevent type 1 diabetes
(T1D), invites Letters of Intent (LOI) for the discovery and validation of novel glucose responsive insulin
(GRI) drugs for better treatment of insulin-dependent diabetes mellitus (IDDM) and reducing the burden of daily management of the disease, particularly T1D.

Proposals (supported by strong rationale and/or preliminary data) will be considered for a maximum
budget of up to $500,000* per year for up to 3 years of funding (including 10% indirect costs)

* Applications whose budget and/or timeline exceeds the above specified guidelines, must
obtain JDRF staff approval prior to submitting an LOI

OBJECTIVES

Letters of intent are sought from academic or industry applicants with innovative approaches to discover and
provide validation (proof-of-concept) for insulin delivery proportional to circulating real time levels of blood glucose in animal models of T1D.

Early concepts with limited preliminary results may be considered at reduced scope, budget and timelines
based on strength of hypothesis and feasibility of approach.

Designing glucose-responsive insulins may require a concerted effort from various areas of expertise.
Therefore, applications from a network of investigators and/or collaborations leveraging expertise in protein biochemistry, pharmacology, drug delivery, formulation sciences, bioengineering and other fields, as applicable, will be given a high priority.

Alternately, JDRF Staff may suggest collaborations between two or more applicants based upon complementarity to form a network.

Expected outcomes from project proposals would demonstrate but be not limited to:

-- Insulin release and blood glucose lowering proportional to circulating levels of glucose

-- Improvements in glycemic parameters–glucose tolerance, reduced hypoglycemia, etc.

-- Reversibility of mechanism

-- Safety and tolerability of biomaterials, excipients, etc.

-- Pharmacokinetic and pharmacodynamic measures

-- Evidence of elimination of biomaterials, if any

Applications should contain an analysis of the projected GRI product concept compared to standard-of-
care, including:

-- Target Product Profile and Target Patient Profile

-- Reduced frequency of dosing (such as once-a-day)

-- Reduced need for monitoring blood glucose levels

-- Reduced risk for hypo and hyperglycemia

-- Timelines for development

-- Cost/benefit analysis

-- Competitive landscape

Applicants are encouraged to consult with JDRF Scientific Staff to discuss the alignment of their proposal to this RFA and in developing the projected GRI product concept

Collaborations with industry and/or direct applications by companies are strongly encouraged.

Request for Expressions of Interest: Exploratory Clinical Trials of Non-insulin Adjunct Therapies in Type 1 Diabetes

ScanGrants - Diabetes -

Request for Expressions of Interest: Exploratory Clinical Trials of Non-insulin Adjunct Therapies in Type 1 Diabetes

Expression of Interest Deadline: July 11, 2014

JDRF, the world’s leading non-profit organization with the mission to cure, treat and prevent type 1 diabetes (T1D), invites Expressions of Interest (EOI) for clinical trials to evaluate non-insulin based adjunct therapies for improved glycemic and overall metabolic control of T1D.

JDRF has an unprecedented opportunity to make progress in the clinical assessment of adjunctive therapies for T1D that move beyond an insulin-centric view of the disease.

At present, several agents–mostly approved T2D therapies such as incretins, SGLT inhibitors, metformin–
are under clinical investigation to assess the benefit: risk profile in T1D. However, a systematic clinical phenotyping of the heterogeneous disease to enable personalized interventions addressing specific dysfunctional pathways or an understanding of the mechanistic pathology is yet to be undertaken. It is our goal to de-convolute the T1D disease complexity such that sub-groups of individuals can be identified and stratified to determine optimal therapeutic regimen of non-insulin adjunct therapies, thus maximizing the benefit: risk ratio for the patients.

JDRF wishes to solicit expressions of interest for clinical trials in established from academic and industry
applicants T1D to test the safety, efficacy, and potential synergies of adjunct therapies that target multiple facets of the disease.

Request for Letters of Intent: Exploratory Clinical Trials for Diabetic Retinopathy

ScanGrants - Diabetes -

Request for Letters of Intent: Exploratory Clinical Trials for Diabetic Retinopathy

LOI Submission Deadline: .June 20th 2014

JDRF is committed to facilitating the translation of therapies for diabetic retinopathy to individuals with Type 1 Diabetes (T1D). To this end, JDRF is soliciting letters of intent for clinical trials of novel therapies for non-proliferative (NPDR), or proliferative retinopathy (PDR).

Diabetic retinopathy is a sight-threatening complication of diabetes and the largest cause of blindness in the US. Despite recent advances in the treatment of diabetic macular edema, there remains a large unmet clinical need to prevent or reverse vision loss via the treatment of NPDR and PDR.

OBJECTIVES

Letters of intent are sought from investigators with for innovative approaches to arrest or reverse NPDR or
to resolve PDR.

Exploratory and initial proof of concept clinical trials which could provide a strong scientific rationale for larger or pivotal studies will be given highest priority.

Clinical trials must include subjects with T1D; however trials will be considered which also propose enrollment of those with Type 2 Diabetes (T2D). Proof of concept clinical studies may propose use of approved or investigational products based on an excellent scientific rationale. JDRF is particularly interested in clinical trials which propose novel means of subject stratification based on estimated risk of progression of NPDR.

Endpoints of interest include: Change in ETDRS scale; prevention of progress ion or improvement

Visual acuity

Other well-justified measures of visual function

Progression to proliferative diabetic retinopathy

Vision-related quality of life scores

Clinical trials of up to 36 months duration will be considered. Investigators proposing trials exceeding this duration should contact Dr Helen Nickerson to assess whether submission is possible.

Under exceptional circumstances, proposals which also include preclinical studies may be considered if needed to obtain regulatory approval to move forward with the proposed clinical trial. Please contact Dr Helen Nickerson to discuss studies in this area.

Request for Expressions of Interest: Clinical Trials to Preserve Beta Cell Function and Delay Onset of Symptomatic Disease in the At-risk Setting for Type 1 Diabetes (T1D)

ScanGrants - Diabetes -

Request for Expressions of Interest: Clinical Trials to Preserve Beta Cell Function and Delay Onset of Symptomatic Disease in the At-risk Setting for Type 1 Diabetes (T1D)

Expression of Interest deadline: July 11, 2014

JDRF is soliciting expressions of interest (EOI) for performing secondary prevention clinical trials to preserve beta cell function and delay the onset of symptomatic disease.

These EOIs may include proof-of-concept clinical trials with existing and/or novel therapies and with combination therapies that target different aspects of beta cell dysfunction and loss.

Objectives

Expressions of interest are sought from investigators with access to patient cohorts of individuals with ≥2
T1D autoantibodies to conduct proof-of-concept clinical trials using intermediate trial outcomes/endpoints
to inform larger and longer prevention trials. Intermediate endpoints to be considered include: increasing
HbA1c, onset of dysglycemia, reversal of dysglycemia, change in C-peptide, etc.). Repurposed and/or
novel therapeutics (immune, inflammation, beta cell survival, metabolic, etc.) will be considered.
Combination therapies, used either sequentially or simultaneously, for robust prevention will also be
considered.

Investigators with ideas or resources that might benefit this initiative should also submit their ideas via an
expression of interest.

Mechanistic studies should be built into all trials.

JDRF is concurrently releasing an EOI for Combination Therapies in Type 1 Diabetes.

This EOI is not meant as a replication of that EOI, which focuses on combination therapies for new-onset and established T1D.

Furthermore, EOIs with a focus on primary prevention will not be considered

Mechanism

EOIs in response to this announcement can be submitted to the following mechanism:

Clinical Strategic Research Agreements (supported by strong preliminary data) for a maximum budget of
$1,500,000* per year for up to 3 years of funding (including 10% indirect costs)

Pre-clinical support may be requested only for IND-enabling activities.

* Applications whose budget and/or timeline exceeds the above specified guidelines, must obtain JDRF
staff approval prior to submitting an LOI.

Applications that are not funded in this competition may be resubmitted to other JDRF grant mechanisms
according to the deadlines and guidelines described on the JDRF Web site:
http://www.jdrf.org/

Pages

Subscribe to PlantBasedResearch aggregator